IS5345A - Samsett meðferð sem inniheldur amlódipín og statín efnasambönd - Google Patents

Samsett meðferð sem inniheldur amlódipín og statín efnasambönd

Info

Publication number
IS5345A
IS5345A IS5345A IS5345A IS5345A IS 5345 A IS5345 A IS 5345A IS 5345 A IS5345 A IS 5345A IS 5345 A IS5345 A IS 5345A IS 5345 A IS5345 A IS 5345A
Authority
IS
Iceland
Prior art keywords
combination therapy
statin compounds
therapy containing
containing amlodipine
amlodipine
Prior art date
Application number
IS5345A
Other languages
English (en)
Inventor
Andrew Donald Scott Robert
Buch Jan
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5345(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5345A publication Critical patent/IS5345A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS5345A 1997-08-29 2000-01-14 Samsett meðferð sem inniheldur amlódipín og statín efnasambönd IS5345A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29
PCT/IB1998/001220 WO1999011263A1 (en) 1997-08-29 1998-08-10 Combination therapy comprising amlodipine and a statin compound

Publications (1)

Publication Number Publication Date
IS5345A true IS5345A (is) 2000-01-14

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5345A IS5345A (is) 1997-08-29 2000-01-14 Samsett meðferð sem inniheldur amlódipín og statín efnasambönd

Country Status (37)

Country Link
US (1) US20020025981A1 (is)
EP (1) EP1003507A1 (is)
JP (1) JP2001514224A (is)
KR (1) KR20010022385A (is)
CN (1) CN1117566C (is)
AP (1) AP1207A (is)
AR (1) AR017514A1 (is)
AU (1) AU744982B2 (is)
BG (1) BG104076A (is)
BR (1) BR9811558A (is)
CA (1) CA2296726C (is)
CO (1) CO4970726A1 (is)
DZ (1) DZ2600A1 (is)
EA (1) EA002705B1 (is)
GT (1) GT199800134A (is)
HK (1) HK1029530A1 (is)
HN (1) HN1998000124A (is)
HR (1) HRP980475A2 (is)
HU (1) HUP0003103A3 (is)
ID (1) ID24275A (is)
IL (2) IL133957A0 (is)
IS (1) IS5345A (is)
MA (1) MA26539A1 (is)
NO (1) NO20000999L (is)
NZ (1) NZ502283A (is)
OA (1) OA11289A (is)
PA (1) PA8457201A1 (is)
PE (1) PE106999A1 (is)
PL (1) PL339088A1 (is)
SA (1) SA98190432A (is)
SK (1) SK1392000A3 (is)
TN (1) TNSN98158A1 (is)
TR (1) TR200000562T2 (is)
UY (1) UY25159A1 (is)
WO (1) WO1999011263A1 (is)
YU (1) YU2700A (is)
ZA (1) ZA987843B (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
WO2007111027A1 (ja) * 2006-03-29 2007-10-04 Kowa Co., Ltd. トリグリセリド低下剤及び高インスリン血症改善剤
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR20090091085A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 약제학적 제제
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
KR20100008356A (ko) * 2008-07-15 2010-01-25 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
PE20180027A1 (es) * 2015-02-06 2018-01-09 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapia combinada
WO2019094581A1 (en) * 2017-11-10 2019-05-16 Op-T Llc Methods for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US20240091147A1 (en) * 2019-11-25 2024-03-21 Fordoz Pharma Corp. Oral liquid formulations of lipid-lowering and blood pressure-lowering drugs
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (is) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
YU2700A (sh) 2002-06-19
BR9811558A (pt) 2000-08-22
IL133957A0 (en) 2001-04-30
GT199800134A (es) 2000-02-08
WO1999011263A1 (en) 1999-03-11
CA2296726A1 (en) 1999-03-11
ZA987843B (en) 2000-02-28
EA002705B1 (ru) 2002-08-29
HK1029530A1 (en) 2001-04-06
SA98190432A (ar) 2005-12-03
CN1268054A (zh) 2000-09-27
UY25159A1 (es) 2000-12-29
AP1207A (en) 2003-09-20
MA26539A1 (fr) 2004-12-20
HUP0003103A2 (hu) 2001-01-29
ID24275A (id) 2000-07-13
EP1003507A1 (en) 2000-05-31
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15
JP2001514224A (ja) 2001-09-11
AR017514A1 (es) 2001-09-12
AU8458598A (en) 1999-03-22
AU744982B2 (en) 2002-03-07
HN1998000124A (es) 1999-02-09
DZ2600A1 (fr) 2003-03-01
CN1117566C (zh) 2003-08-13
BG104076A (en) 2000-09-29
AP9801333A0 (en) 1998-09-30
EA200000013A1 (ru) 2000-08-28
CO4970726A1 (es) 2000-11-07
HRP980475A2 (en) 1999-06-30
TR200000562T2 (tr) 2000-08-21
KR20010022385A (ko) 2001-03-15
PL339088A1 (en) 2000-12-04
CA2296726C (en) 2004-06-29
IL133957A (en) 2006-06-11
US20020025981A1 (en) 2002-02-28
PA8457201A1 (es) 2000-05-24
NZ502283A (en) 2002-05-31
NO20000999D0 (no) 2000-02-28
HUP0003103A3 (en) 2002-03-28
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
NO20000999L (no) 2000-02-28

Similar Documents

Publication Publication Date Title
IS5345A (is) Samsett meðferð sem inniheldur amlódipín og statín efnasambönd
IS5341A (is) Samsett meðferð sem inniheldur atórvastatin og þrýstingslækkandi miðil
ATE332689T1 (de) Therapeutische zusammensetzungen, enthaltend amlodipin und atorvastatin
EP1037635A4 (en) CONNECTIONS AROUND METHODS
NO983187L (no) Substituerte aza- og diazacykloheptan og -cyklooktan-forbindelse og deres anvendelse
HUP0003636A3 (en) Analgesic combination
ZA988749B (en) New pieperazine and piperidine compounds
GB9704349D0 (en) Levobupivacaine and its use
EP1032559A4 (en) AMINO-ALKYLPHENOL DERIVATIVES AND ASSOCIATED COMPOUNDS
GB9704370D0 (en) Levobupivacaine and its use
EP1112250A4 (en) THERAPEUTIC COMPOUNDS AND RELATED METHODS
EP1135023A4 (en) AMINOBENZISOXAZOLE COMPOUNDS AND LIBRARIES THEREOF
PL351408A1 (en) Synergistic effects of amlodipine and atorvastatin
DK1042286T3 (da) Gamme-glutamyl- og beta-aspartyl-holdige immunmodulerende forbindelser og tilhørense fremgangsmåder
EP1150967A4 (en) THERAPEUTICALLY APPLICABLE CONNECTIONS AND METHODS
GB9722023D0 (en) Levobupivacaine and its use
GB2321203B (en) Gaming-table and barrier therefor
GB9724506D0 (en) Levobupivacaine and its use
GB9722022D0 (en) Levobupivacaine and its use
GB9715462D0 (en) levobupivacaine and its use
GB9715322D0 (en) Levobupivacaine and its use
GB9710080D0 (en) Levobupivacaine and its use
GB9704369D0 (en) Levobupivacaine and its use
ZA200108685B (en) Synergistic effects of amlodipine and atorvastatin.
PL107276U1 (en) Smoke gate